KalVista Pharmaceuticals (KALV) Tops Q2 EPS by 4c
Tweet
Share
E-mailGet Alerts KALV Hot Sheet
Join SI Premium – FREE
KalVista Pharmaceuticals (NASDAQ: KALV) reported Q2 EPS of ($0.92), $0.04 better than the analyst estimate of ($0.96). Revenue for the quarter came in at $13.69 million versus the consensus estimate of $7.17 million.
For earnings history and earnings-related data on KalVista Pharmaceuticals (KALV) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BofA maintains underperform ratings on six BDC stocks
- Cytek faces $56M damages award in Beckman Coulter patent case
- CoVolt Power files for proposed IPO
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
